Mohammed Milhem, MBBS discussed the mechanism of action of RP1, the design and preliminary findings of the IGNYTE trial in ...

The global oncolytic virus cancer therapy market is poised for exceptional growth, expanding from an estimated USD 36.87 million in 2025 to an impressive USD 386.89 million by 2035, marking a Compound ...

Successfully translating this discovery, the company’s therapeutic approach revolves around the use of armed ... and CEO Akseli Hemminki. “Our oncolytic viruses better enable T cells to ...

To that end, Dr. Gujar and colleagues around the world who are ... standards on the development and usage of viruses to fight cancer, known as oncolytic viruses (OVs). Dr. Gujar, along with ...

The main driving factor for the Oncolytic Virus Immunotherapy market is the rising cancer prevalence worldwide. By 2040, the global number will rise to 27.5 million new cancer patients and around 16.3 ...

Oncolytic viruses, once considered medical curiosities, are now cutting-edge tools in the fight against some of the most challenging cancers, like glioblastoma. These tiny engineered viruses ...

It's not the first therapy in the oncolytic virus class to be approved around the world, as that accolade went to Amgen's Imlygic (talimogene laherparepvec), which was cleared by the FDA for the ...

There are around 2,800 new cases of malignant glioma ... participated in the clinical trial programme. It is the first oncolytic virus therapy to be launched anywhere in the world for brain ...

Bacillus Calmette-Guérin (BCG) remains the primary treatment for patients with high-risk bladder cancer, but resistance develops in 30% to 40% of cases. The use of oncolytic viruses has emerged as a ...